Boise Cascade (BCC)

Volatility is back, and while it's normal, fear dominates. Investors are uneasy despite no official correction, as past gains spoiled expectations. Economic uncertainty, rising debt, and inflation ris...

The market's volatility, driven by geopolitical tensions and tariffs, has created a challenging environment. The sentiment is bearish, but I see opportunities in undervalued, high-quality companies wi...

Medicus Pharma (NASDAQ:MDCX) has revealed interim results from its Phase 2 clinical trial for a non-invasive treatment targeting basal cell carcinoma (BCC) showing promising efficacy and safety outcom...

The Interim Analysis Showed Complete Clinical Clearance of More than Sixty (60%) Percent Philadelphia, Pennsylvania--(Newsfile Corp. - March 6, 2025) - Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or...

The Clinical Study is Expected to Randomize 36 Participants in Cleveland Clinic Abu Dhabi (CCAD) and Three Other Clinical Sites in UAE Philadelphia, Pennsylvania--(Newsfile Corp. - February 27, 2025) ...

BCC's fourth-quarter 2024 results reflect unfavorable sales price trends. Dive in to learn more about the quarterly performance.

BOISE, Idaho--(BUSINESS WIRE)--Boise Cascade Company (Boise Cascade) (NYSE: BCC) announced today that Nathan Sikes will be the new Senior Vice President of Western Operations for their Building Materi...

Boise Cascade Company, Inc. (NYSE:BCC ) Q4 2024 Earnings Conference Call February 21, 2025 11:00 AM ET Company Participants Chris Forrey - VP, Finance & IR Nathan Jorgensen - CEO & Director Kelly Hibb...

Boise Cascade (BCC) came out with quarterly earnings of $1.78 per share, missing the Zacks Consensus Estimate of $1.82 per share. This compares to earnings of $2.44 per share a year ago.

BOISE, Idaho--(BUSINESS WIRE)--Boise Cascade Company ("Boise Cascade," the "Company," "we," or "our") (NYSE: BCC) today reported fourth quarter net income of $68.9 million, or $1.78 per share, on sale...